ORIGINAL RESEARCH article
Front. Neurol.
Sec. Multiple Sclerosis and Neuroimmunology
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1619479
Serum Homocysteine Levels Predict Poor Recovery and Relapse in First-Attack Myelin Oligodendrocyte Glycoprotein Antibody Disease
Provisionally accepted- First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background and objective: Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is an inflammatory demyelinating disease with a high risk of recurrence and progressive disability, and it is crucial to find sensitive and reliable biomarkers for prognosis and the early prediction of relapse. In the study we investigated whether serum homocysteine (Hcy) levels are associated with a poor prognosis or risk of relapse in patients with first-attack MOGAD.We enrolled patients diagnosed as having first-attack MOGAD between January 2019 and December 2024 in this retrospective study. Clinical data and initial Expanded Disability Status Scale (EDSS) scores were collected and analyzed. Clinical outcomes were measured using the final EDSS score and relapse events. We used logistic regression models and Cox regression analysis to determine the association between Hcy levels and clinical recovery and relapse.Results: Seventy patients (female, n=36; male, n=34) with first-attack MOGAD were included in this study.The final EDSS scores (P=0.015) and relapse rates (P=0.039) were higher in the high Hcy group than in the normal Hcy group. Multivariate analysis results indicated that Hcy levels (odds ratio [OR] 1.126; 95% confidence interval [CI] 1.005-1.261, P=0.04) and the initial EDSS scores (OR 2.017, 95% CI 1.266-3.214, P=0.003) were independent risk factors for predicting poor recovery. Kaplan-Meier survival analysis showed that Hcy levels were a predictor of relapse in patients with MOGAD (log-rank test P=0.029). The results of the multivariate Cox proportional hazards model indicated that Hcy levels (hazard ratio [HR] 1.088, 95% CI 1.020-1.161, P=0.011) were related to MOGAD relapse.We identified Hcy levels as an independent risk factor for predicting poor clinical recovery in patients with first-attack MOGAD. Hcy levels were also significantly associated with the relapse of MOGAD.
Keywords: Homocysteine, first-attack myelin oligodendrocyte glycoprotein antibody disease, predictor, relapse, Recovery
Received: 28 Apr 2025; Accepted: 07 Jul 2025.
Copyright: © 2025 Li and Jia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yanjie Jia, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.